These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16268330)

  • 1. Molecular genetics goes to the diabetes clinic.
    Hattersley AT
    Clin Med (Lond); 2005; 5(5):476-81. PubMed ID: 16268330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes.
    Pearson ER; Liddell WG; Shepherd M; Corrall RJ; Hattersley AT
    Diabet Med; 2000 Jul; 17(7):543-5. PubMed ID: 10972586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maturity onset diabetes of the young: identification and diagnosis.
    McDonald TJ; Ellard S
    Ann Clin Biochem; 2013 Sep; 50(Pt 5):403-15. PubMed ID: 23878349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A family with a novel termination mutation in hepatic nuclear factor 1α in maturity-onset diabetes of the young type 3 which is unresponsive to sulphonylurea therapy.
    Demol S; Lebenthal Y; Bar-Meisels M; Phillip M; Gat-Yablonski G; Gozlan Y
    Horm Res Paediatr; 2014; 81(4):280-4. PubMed ID: 24642958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment.
    Schnedl WJ; Holasek SJ; Schenk M; Enko D; Mangge H
    Wien Klin Wochenschr; 2021 Mar; 133(5-6):241-244. PubMed ID: 33245425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of new mutation in maturity-onset diabetes of the young type 3 (MODY 3) responsive to a low dose of sulphonylurea.
    Jesić MD; Sajić S; Jesić MM; Maringa M; Micić D; Necić S
    Diabetes Res Clin Pract; 2008 Jul; 81(1):e1-3. PubMed ID: 18433912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic causes and treatment of neonatal diabetes and early childhood diabetes.
    Barbetti F; D'Annunzio G
    Best Pract Res Clin Endocrinol Metab; 2018 Aug; 32(4):575-591. PubMed ID: 30086875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
    Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MODY in Ukraine: genes, clinical phenotypes and treatment.
    Globa E; Zelinska N; Elblova L; Dusatkova P; Cinek O; Lebl J; Colclough K; Ellard S; Pruhova S
    J Pediatr Endocrinol Metab; 2017 Oct; 30(10):1095-1103. PubMed ID: 28862987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis in diabetes: does it matter?
    Thethy I; Robertson L; Swaminathan K
    J R Coll Physicians Edinb; 2011 Jun; 41(2):119-21. PubMed ID: 21677915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical parameters for molecular testing of Maturity Onset Diabetes of the Young (MODY)].
    Datz N; Nestoris C; von Schütz W; Danne T; Driesel AJ; Maringa M; Kordonouri O
    Dtsch Med Wochenschr; 2011 May; 136(21):1111-5. PubMed ID: 21590629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes.
    Hattersley AT; Pearson ER
    Endocrinology; 2006 Jun; 147(6):2657-63. PubMed ID: 16556760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monogenic models: what have the single gene disorders taught us?
    Klupa T; Skupien J; Malecki MT
    Curr Diab Rep; 2012 Dec; 12(6):659-66. PubMed ID: 22996131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maturity-onset diabetes of the young (MODY): an update.
    Anık A; Çatlı G; Abacı A; Böber E
    J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):251-63. PubMed ID: 25581748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
    Ellard S; Colclough K
    Hum Mutat; 2006 Sep; 27(9):854-69. PubMed ID: 16917892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ISPAD Clinical Practice Consensus Guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents.
    Rubio-Cabezas O; Hattersley AT; Njølstad PR; Mlynarski W; Ellard S; White N; Chi DV; Craig ME;
    Pediatr Diabetes; 2014 Sep; 15 Suppl 20():47-64. PubMed ID: 25182307
    [No Abstract]   [Full Text] [Related]  

  • 17. Maturity onset diabetes of the young: Seek and you will find.
    Heuvel-Borsboom H; de Valk HW; Losekoot M; Westerink J
    Neth J Med; 2016 Jun; 74(5):193-200. PubMed ID: 27323672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When to consider a diagnosis of MODY at the presentation of diabetes: aetiology matters for correct management.
    Juszczak A; Pryse R; Schuman A; Owen KR
    Br J Gen Pract; 2016 Jun; 66(647):e457-9. PubMed ID: 27231307
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment.
    Schnyder S; Mullis PE; Ellard S; Hattersley AT; Flück CE
    Swiss Med Wkly; 2005 Jun; 135(23-24):352-6. PubMed ID: 16059790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients.
    Shepherd M; Shields B; Ellard S; Rubio-Cabezas O; Hattersley AT
    Diabet Med; 2009 Apr; 26(4):437-41. PubMed ID: 19388975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.